Place · Level 3 · Vitamin
Vitamin K1 (Phylloquinone)
绿叶里的凝血因子激活剂 · γ-羧化让 II/VII/IX/X 抓住钙 · 新生儿出血预防 · 华法林为何要稳
Last updated
Story path
Chapter 1
K1 lives in leaves
K1 lives in leaves
Vitamin K1 (phylloquinone) is part of the chloroplast machinery in plant leaves, where it participates in photosynthetic electron transport. The greener the leaf, the higher the K1:
Kale, cooked, 100 g: ~820 µg — the leaderSpinach, cooked, 100 g: ~540 µgBroccoli, cooked, 100 g: ~140 µgLettuce (large leaf), 100 g: ~50-100 µgSoybean / canola oil: moderate amounts — one of the main K1 sources in Western diets
AI (Adequate Intake, IOM) targets: 120 µg/day men, 90 µg/day women — a single cup of cooked spinach exceeds the daily target.
K1 vs K2 division of labor: K1 mainly serves the liver, activating clotting factors II / VII / IX / X; K2 takes the osteocalcin + MGP path (see the Atlas vitamin-k2 story). Structurally the head is the same (naphthoquinone core); the difference is in the tail — K1 has a single isoprenoid side chain, K2 has multiple (MK-4 to MK-13). The body can interconvert small amounts of K1 → MK-4, but not enough to cover the full range of K2 functions.
'I eat greens daily, I shouldn't be K1-deficient' is essentially correct — this is one of nutrition teaching's rare 'if the diet structure is normal, you're covered' cases. Real K1 deficiency occurs in: long-term TPN (parenteral nutrition), severe fat malabsorption, long-term broad-spectrum antibiotic use, anticonvulsant use, and newborns (see later scene).
Kale, cooked, 100 g: ~820 µg — the leaderSpinach, cooked, 100 g: ~540 µgBroccoli, cooked, 100 g: ~140 µgLettuce (large leaf), 100 g: ~50-100 µgSoybean / canola oil: moderate amounts — one of the main K1 sources in Western diets
AI (Adequate Intake, IOM) targets: 120 µg/day men, 90 µg/day women — a single cup of cooked spinach exceeds the daily target.
K1 vs K2 division of labor: K1 mainly serves the liver, activating clotting factors II / VII / IX / X; K2 takes the osteocalcin + MGP path (see the Atlas vitamin-k2 story). Structurally the head is the same (naphthoquinone core); the difference is in the tail — K1 has a single isoprenoid side chain, K2 has multiple (MK-4 to MK-13). The body can interconvert small amounts of K1 → MK-4, but not enough to cover the full range of K2 functions.
'I eat greens daily, I shouldn't be K1-deficient' is essentially correct — this is one of nutrition teaching's rare 'if the diet structure is normal, you're covered' cases. Real K1 deficiency occurs in: long-term TPN (parenteral nutrition), severe fat malabsorption, long-term broad-spectrum antibiotic use, anticonvulsant use, and newborns (see later scene).
数字 · 哪些菜的 K1 最多
绿色越深，K1 含量越高：羽衣甘蓝熟 100 g：约 820 µg，排第一菠菜熟 100 g：约 540 µg西兰花熟 100 g：约 140 µg生菜大叶 100 g：约 50-100 µg大豆油、菜籽油：含量中等，是西方饮食里 K1 的主力之一
AI (Adequate Intake, IOM) 给的目标量：成人男 120 µg/天，女 90 µg/天——一杯熟菠菜就远超。
K1 和 K2 结构上差在哪：两者的头部相同 (萘醌核)，区别在尾巴——K1 是单异戊二烯侧链，K2 是多重 (MK-4 到 MK-13)。身体可以把少量 K1 内转成 MK-4，但不足以覆盖 K2 的全部功能。
Greens-thicken-blood myth
'Greens are high in vitamin K, eating more thickens the blood and raises clot risk' — for almost everyone this is completely wrong.Comparing the data point by point: in healthy adults at K1 intakes between 50 and 800 µg/day, prothrombin time (PT / INR) barely moves; the body only uses what it needs to γ-carboxylate clotting factors, and excess K1 is metabolized in the liver and excreted; epidemiology shows no dose-response relationship between 'high K1' and clotting events; observational data actually point the opposite way — people who eat more greens have fewer cardiovascular events (composite of K2, folate, potassium, fiber, and nitrates).
The only people who really need stable K1 intake are patients on warfarin. But the answer is not 'avoid greens', it's 'eat about the same amount every day' — the physician sets the warfarin dose against that baseline (see the anticoagulants scene).
Patients on DOACs (dabigatran / rivaroxaban / apixaban / edoxaban) bypass the K cycle entirely — eat all the greens you want.
So for ordinary people, more greens carry no clotting risk. The claim's origin traces to 1990s 'spinach + warfarin' clinical cases that were incorrectly generalized to healthy populations — the vascular protection of greens far outweighs any imagined 'thicker blood' risk.
Chapter 2
Gut absorption · fat-soluble
Gut absorption · fat-soluble
K1 is fat-soluble, in the same group as A / D / E, and needs to be eaten with fat for proper absorption.
Absorption path (in order):
1. Duodenum / upper jejunum: dietary K1 is embedded in chloroplast thylakoid membranes; bile acids and pancreatic lipase dissolve it out, emulsifying into mixed micelles.
2. Enterocyte: uptake via the NPC1L1 receptor plus passive diffusion.
3. Packaged into chylomicrons: into lymph, then into venous circulation, finally to the liver.
4. Liver: K1 is mostly taken up by hepatocytes; storage is minimal (only 1-2 days of supply), so daily intake is required.
Absorption efficiency ~10-15%, lower than D or E. Key modifiers:
Raw vs cooked: cooked greens absorb 2-3× better than raw — heat opens cell walls and oil helps dissolveAdding oil: salad drizzled with olive oil + avocado can multiply K1 absorption several-foldWhole leaves vs juice: green juice has high free K1 but lacks the fat carrier, so actual absorption is worse than 'vegetables + oil'
Poor-absorption populations:
Cystic fibrosis (CF) or chronic pancreatitis: pancreatic lipase insufficiency → fat-soluble vitamin K deficiencyBile acid deficiency (biliary obstruction / severe liver disease): can't form micellesCrohn's, short bowel syndrome, severe gluten intolerance: distal small bowel or colon dysfunctionOrlistat (weight-loss drug): blocking fat absorption blocks KBile-acid sequestrant resins (cholestyramine): same blockageLong-term broad-spectrum antibiotics: gut bacterial long-chain MK synthesis falls, affecting K2 more than K1 but compounding
Practical: healthy adults are fine with greens + fat + normal diet; people with absorption disorders can work with their dietitian or GI team on water-solubilized K1 (Konakion MM, micellar form) or injectable forms; infants in the first few months have immature GI tracts and very low K1 in breast milk, so an IM shot at birth is standard (see next scene).
Absorption path (in order):
1. Duodenum / upper jejunum: dietary K1 is embedded in chloroplast thylakoid membranes; bile acids and pancreatic lipase dissolve it out, emulsifying into mixed micelles.
2. Enterocyte: uptake via the NPC1L1 receptor plus passive diffusion.
3. Packaged into chylomicrons: into lymph, then into venous circulation, finally to the liver.
4. Liver: K1 is mostly taken up by hepatocytes; storage is minimal (only 1-2 days of supply), so daily intake is required.
Absorption efficiency ~10-15%, lower than D or E. Key modifiers:
Raw vs cooked: cooked greens absorb 2-3× better than raw — heat opens cell walls and oil helps dissolveAdding oil: salad drizzled with olive oil + avocado can multiply K1 absorption several-foldWhole leaves vs juice: green juice has high free K1 but lacks the fat carrier, so actual absorption is worse than 'vegetables + oil'
Poor-absorption populations:
Cystic fibrosis (CF) or chronic pancreatitis: pancreatic lipase insufficiency → fat-soluble vitamin K deficiencyBile acid deficiency (biliary obstruction / severe liver disease): can't form micellesCrohn's, short bowel syndrome, severe gluten intolerance: distal small bowel or colon dysfunctionOrlistat (weight-loss drug): blocking fat absorption blocks KBile-acid sequestrant resins (cholestyramine): same blockageLong-term broad-spectrum antibiotics: gut bacterial long-chain MK synthesis falls, affecting K2 more than K1 but compounding
Practical: healthy adults are fine with greens + fat + normal diet; people with absorption disorders can work with their dietitian or GI team on water-solubilized K1 (Konakion MM, micellar form) or injectable forms; infants in the first few months have immature GI tracts and very low K1 in breast milk, so an IM shot at birth is standard (see next scene).
数字 · 吸收效率与怎么吃
肝里的存量只够用 1-2 天：K1 几乎不囤货，所以它必须天天从饭里续上。整条路的吸收效率只有约 10-15%，比 D 和 E 都低，而且很看你怎么吃：
熟菜比生菜好吸收 2-3 倍——加热把细胞壁打开，油又帮着溶解淋点橄榄油、配块牛油果，还能再往上抬打成汁喝：游离的 K1 是多了，却少了油这个载体，实际吸收反而不如一盘菜配油
哪些病会挡住这条路：囊性纤维化、慢性胰腺炎 (胰脏脂肪酶不足)；胆管堵塞、重症肝病 (胆汁出不来，油水小球组不起来)；克罗恩、短肠 (小肠吸收面受损)。
Chapter 3
γ-carboxylation cycle
γ-carboxylation cycle
K1's job is to give a specific group of proteins 'calcium-gripping ability' — via γ-carboxylation, converting Glu (glutamate) residues into Gla (γ-carboxyglutamate). The reaction takes place in the hepatic endoplasmic reticulum; the main enzyme is GGCX (γ-glutamyl carboxylase), with reduced K1 (hydroquinone, KH₂) as cofactor.
The 5-step reaction cycle:
1. KH₂ + O₂ → forms a strong base intermediate that abstracts a proton from the Glu side chain
2. Naked Glu residue + CO₂ → forms a new C-C bond → Gla (one extra carboxyl group)
3. KH₂ is oxidized in this step to K1-2,3-epoxide (K1-O), now inactive
4. VKORC1 (vitamin K epoxide reductase complex 1) reduces K1-O back to KH₂, ready for the next cycle
5. The whole cycle closes and the cofactor is reused: one K1 molecule can activate tens to hundreds of clotting factor proteins
Why Gla matters: Gla's two carboxyls carry negative charges, acting like tiny calcium clamps that grip Ca²⁺ electrostatically; clotting factors with Gla can then bind Ca²⁺ on phospholipid membrane surfaces and assemble into clotting complexes. Without Gla, factors float in blood completely non-functional.
This cycle is warfarin's target: warfarin precisely inhibits VKORC1 → K1-O can't be reduced back to KH₂ → GGCX stalls → newly synthesized clotting factors remain in the Glu form (PIVKA, protein induced by vitamin K absence) → clotting time prolonged (INR rises). Conversely, eating K1 directly supplies KH₂, partially bypassing the VKORC1 step and undoing warfarin's effect — this is why 'warfarin + suddenly eating lots of spinach = INR crashes'.
This section's L4 micro-animation steps through GGCX catalysis, VKORC1 recycling of K1-O, and the precise step where warfarin jams — one of the Atlas's most classic 'one molecular switch controls whole-body clotting' cases.
The 5-step reaction cycle:
1. KH₂ + O₂ → forms a strong base intermediate that abstracts a proton from the Glu side chain
2. Naked Glu residue + CO₂ → forms a new C-C bond → Gla (one extra carboxyl group)
3. KH₂ is oxidized in this step to K1-2,3-epoxide (K1-O), now inactive
4. VKORC1 (vitamin K epoxide reductase complex 1) reduces K1-O back to KH₂, ready for the next cycle
5. The whole cycle closes and the cofactor is reused: one K1 molecule can activate tens to hundreds of clotting factor proteins
Why Gla matters: Gla's two carboxyls carry negative charges, acting like tiny calcium clamps that grip Ca²⁺ electrostatically; clotting factors with Gla can then bind Ca²⁺ on phospholipid membrane surfaces and assemble into clotting complexes. Without Gla, factors float in blood completely non-functional.
This cycle is warfarin's target: warfarin precisely inhibits VKORC1 → K1-O can't be reduced back to KH₂ → GGCX stalls → newly synthesized clotting factors remain in the Glu form (PIVKA, protein induced by vitamin K absence) → clotting time prolonged (INR rises). Conversely, eating K1 directly supplies KH₂, partially bypassing the VKORC1 step and undoing warfarin's effect — this is why 'warfarin + suddenly eating lots of spinach = INR crashes'.
This section's L4 micro-animation steps through GGCX catalysis, VKORC1 recycling of K1-O, and the precise step where warfarin jams — one of the Atlas's most classic 'one molecular switch controls whole-body clotting' cases.
机制 · γ-羧化循环的五步
反应位置在肝脏内质网，主角酶是 GGCX (γ-glutamyl carboxylase)，以还原型 K1 (氢醌，KH₂) 为辅因子。反应循环 5 步：
1. KH₂ + O₂ → 形成强碱中间体，把 Glu 上的氢拉走。
2. 裸 Glu 残基 + CO₂ → 形成新的 C-C 键 → Gla (多了一个羧基)。
3. KH₂ 在这一步被氧化成 K1-2,3-环氧化物 (K1-O)，失效。
4. VKORC1 (vitamin K epoxide reductase complex 1) 把 K1-O 还原回 KH₂，进入下一轮。
5. 整个循环闭环复用：一分子 K1 可以激活几十到上百个凝血因子蛋白。
为什么 Gla 重要：Gla 的两个羧基带负电，像几只钙夹，靠静电吸引抓住 Ca²⁺；凝血因子带上 Gla 后才能结合磷脂膜表面的 Ca²⁺，进而组装成凝血复合物。没有 Gla 的因子在血液里游荡，完全没有功能。
Chapter 4
Factors II/VII/IX/X · cascade
Factors II/VII/IX/X · cascade
K1-activated clotting factors total 7 (in hepatic synthesis order):
Factor II (prothrombin): becomes thrombin (IIa) at the end of the cascadeFactor VII: starts the extrinsic pathway; shortest half-life (~4-6 h), so warfarin disables this one first — early INR rise is driven mainly by VII fallingFactor IX: intrinsic pathway; deficiency is hemophilia BFactor X: common pathway, activates thrombinProtein C / S: anticoagulant brake (opposing clotting); on early warfarin Protein C falls faster than the procoagulants, producing a transient hypercoagulable state — this is the chemical basis of the rare 'warfarin skin necrosis' and the rationale for heparin bridgingProtein Z: clotting adjunct
Extrinsic pathway (the main in-vivo initiation): vessel injury → tissue factor (TF) exposed → TF + factor VIIa + Ca²⁺ + phospholipid membrane → activates factor X → Xa + Va + Ca²⁺ + phospholipid → prothrombin (II) → thrombin (IIa) → fibrinogen → fibrin mesh → clot. Every step requires Gla residues anchoring to Ca²⁺ on phospholipid membranes — this is K1's core contribution.
Common clinical lab indicators:
PT (prothrombin time): covers extrinsic + common pathways, sensitive to factors VII / X / II — the primary warfarin monitoring markerINR: PT standardized form, comparable across labsaPTT: intrinsic + common pathways, sensitive to factors IX / VIII / XI — mainly used for heparin monitoringPIVKA-II: under-carboxylated prothrombin; rises in K1 deficiency or warfarin excess; also a hepatocellular carcinoma marker
Clinical signs of severe K1 deficiency (rare): bleeding gums, epistaxis, menorrhagia, easy bruising; PT / INR markedly prolonged, aPTT possibly prolonged (factor IX affected); severe cases can present with GI hemorrhage or intracranial bleeding. Treatment is usually K1 5-10 mg IV or IM; severe cases add PCC (prothrombin complex concentrate) plus transfusion.
Factor II (prothrombin): becomes thrombin (IIa) at the end of the cascadeFactor VII: starts the extrinsic pathway; shortest half-life (~4-6 h), so warfarin disables this one first — early INR rise is driven mainly by VII fallingFactor IX: intrinsic pathway; deficiency is hemophilia BFactor X: common pathway, activates thrombinProtein C / S: anticoagulant brake (opposing clotting); on early warfarin Protein C falls faster than the procoagulants, producing a transient hypercoagulable state — this is the chemical basis of the rare 'warfarin skin necrosis' and the rationale for heparin bridgingProtein Z: clotting adjunct
Extrinsic pathway (the main in-vivo initiation): vessel injury → tissue factor (TF) exposed → TF + factor VIIa + Ca²⁺ + phospholipid membrane → activates factor X → Xa + Va + Ca²⁺ + phospholipid → prothrombin (II) → thrombin (IIa) → fibrinogen → fibrin mesh → clot. Every step requires Gla residues anchoring to Ca²⁺ on phospholipid membranes — this is K1's core contribution.
Common clinical lab indicators:
PT (prothrombin time): covers extrinsic + common pathways, sensitive to factors VII / X / II — the primary warfarin monitoring markerINR: PT standardized form, comparable across labsaPTT: intrinsic + common pathways, sensitive to factors IX / VIII / XI — mainly used for heparin monitoringPIVKA-II: under-carboxylated prothrombin; rises in K1 deficiency or warfarin excess; also a hepatocellular carcinoma marker
Clinical signs of severe K1 deficiency (rare): bleeding gums, epistaxis, menorrhagia, easy bruising; PT / INR markedly prolonged, aPTT possibly prolonged (factor IX affected); severe cases can present with GI hemorrhage or intracranial bleeding. Treatment is usually K1 5-10 mg IV or IM; severe cases add PCC (prothrombin complex concentrate) plus transfusion.
临床 · 验血看什么、缺了怎么补
为什么华法林一上，最先变的是因子 VII：它是这七个里命最短的，只活约 4-6 h，肝里存的很快用完。所以华法林开始起效的头几天，是它先掉队——验血的数字也因此动得最早。验血看的是哪几个数：凝血酶原时间 (简称 PT) 覆盖组织因子点火的这条路和后半段的共同路，对因子 VII、X、II 最敏感；把不同实验室的 PT 换算到同一把尺子上，就是 INR ——华法林加减剂量看的正是它。
真缺了怎么补：通常是肌注或静脉给 K1 5-10 mg；出血凶时再加凝血酶原复合物 (PCC) 和输血，把因子直接补回来。这些都是医生的处置，不是自己能做的事。
Chapter 5
Newborn K1 shot · VKDB
Newborn K1 shot · VKDB
1 mg IM K1 within 6 hours of birth is one of global public health's most universal 'single-shot vitamin interventions' — recommended by the AAP, WHO, and CDC.
Why infants are K-deficient high risk: the placenta is poorly permeable to K1, so K1 stores at birth are nearly zero; the newborn gut is sterile, with no endogenous K2 synthesis; breast milk has very low K1 (~1-4 µg/L; formula is fortified to ~50 µg/L); the liver is still immature, so clotting factor synthesis is naturally low.
Without supplementation — VKDB (Vitamin K Deficiency Bleeding) three types:
Late VKDB occurs almost exclusively in 'exclusively breast-fed + un-supplemented' infants — a historical lesson: pre-1961, ICH was a common neonatal cause of death; after 1961 standardization of 1 mg IM K1, VKDB incidence dropped from 0.25-1.7% to near zero; in 2000s US, increased parental refusal of the shot brought multiple ICH cases back, and the AAP 2022 strengthened the recommendation.
'K1 injection causes cancer' rumor — origin and rebuttal: the 1992 Golding single-center study incorrectly linked IM K1 to childhood leukemia; 20+ subsequent large cohorts have all refuted this (Roman 2002, McKinney 2003, Parker 2009, Fear 2003); modern consensus is that K1 injection is safe, necessary, and not carcinogenic.
Oral alternative protocols (Netherlands, Denmark, parts of Germany): 2 mg PO × 3 doses (birth / 1 wk / 4 wk) or longer; efficacy approaches injection but requires strict follow-up and has missed-dose risk; biliary atresia infants (occult absorption defect) can still develop late VKDB — which is exactly why the IM shot remains the safety net.
The Day-1 K1 shot is one of the cheapest and most effective public-health interventions in 60 years of neonatal medicine.
Why infants are K-deficient high risk: the placenta is poorly permeable to K1, so K1 stores at birth are nearly zero; the newborn gut is sterile, with no endogenous K2 synthesis; breast milk has very low K1 (~1-4 µg/L; formula is fortified to ~50 µg/L); the liver is still immature, so clotting factor synthesis is naturally low.
Without supplementation — VKDB (Vitamin K Deficiency Bleeding) three types:
| Type | Timing | Location | Death / disability |
|---|---|---|---|
| Early | < 24 h | Visceral / cranial / scalp | Maternal anticoagulant or anticonvulsant related, rare |
| Classic | 1-7 days | GI / umbilical / nasal / skin | Mostly self-limited, mortality 5-15% |
| Late | 2 wk - 6 mo | ~50% present as intracranial hemorrhage (ICH) | Mortality ~20%, ~40% of survivors severely disabled |
Late VKDB occurs almost exclusively in 'exclusively breast-fed + un-supplemented' infants — a historical lesson: pre-1961, ICH was a common neonatal cause of death; after 1961 standardization of 1 mg IM K1, VKDB incidence dropped from 0.25-1.7% to near zero; in 2000s US, increased parental refusal of the shot brought multiple ICH cases back, and the AAP 2022 strengthened the recommendation.
'K1 injection causes cancer' rumor — origin and rebuttal: the 1992 Golding single-center study incorrectly linked IM K1 to childhood leukemia; 20+ subsequent large cohorts have all refuted this (Roman 2002, McKinney 2003, Parker 2009, Fear 2003); modern consensus is that K1 injection is safe, necessary, and not carcinogenic.
Oral alternative protocols (Netherlands, Denmark, parts of Germany): 2 mg PO × 3 doses (birth / 1 wk / 4 wk) or longer; efficacy approaches injection but requires strict follow-up and has missed-dose risk; biliary atresia infants (occult absorption defect) can still develop late VKDB — which is exactly why the IM shot remains the safety net.
The Day-1 K1 shot is one of the cheapest and most effective public-health interventions in 60 years of neonatal medicine.
数字 · 婴儿为什么缺、VKDB 三型与历史
为什么婴儿是 K 缺乏的高危人群：胎盘对 K1 通透性差，出生时 K1 储备几乎为零；新生儿肠道无菌、没有 K2 的内源合成；母乳 K1 含量极低 (~ 1-4 µg/L，配方奶因为有添加约 50 µg/L)；肝脏尚未成熟，合成凝血因子的能力本就低。不补会发生什么——VKDB (Vitamin K Deficiency Bleeding) 三型：
| 类型 | 时间 | 部位 | 死亡、残疾 |
|---|---|---|---|
| 早期 | < 24 h | 内脏、颅 / 头皮 | 母亲服抗凝、抗惊厥相关，罕见 |
| 经典 | 1-7 天 | GI / 脐、鼻 / 皮 | 自限为主，死亡 5-15% |
| 晚期 | 2 周 - 6 月 | 约 50% 表现为颅内出血 (ICH) | 死亡约 20%，幸存约 40% 重残 |
晚期 VKDB 几乎全部发生在纯母乳 + 未补 K1 的婴儿身上——这是历史教训：1960 年代之前 ICH 是新生儿的常见死因；1961 年起 1 mg IM K1 常规化，VKDB 发生率从 0.25-1.7% 降到几乎为零；2000 年代美国拒绝注射 的父母上升，多起 ICH 个案重现，AAP 2022 重新强化了推荐。
误区与替代 · 致癌谣言、口服方案
K1 注射致癌谣言的来源与破解：1992 年 Golding 的单中心研究错误地把 K1 注射和儿童白血病关联起来；后续 20 多项大型队列全部否定了这一结论 (Roman 2002、McKinney 2003、Parker 2009、Fear 2003)；现代共识是 K1 注射安全、必要、不致癌。口服替代方案 (荷兰、丹麦、部分德国)：2 mg PO × 3 次 (出生 / 1 周 / 4 周) 或更长的方案；效果接近注射，但需要严格随访，且存在漏服风险；对胆道闭锁 (隐匿吸收差) 的婴儿仍可能发生晚期 VKDB——这正是注射剂型作为最后保险的价值。
出生第一天的 K1 针，是过去六十年新生儿医学里最便宜也最有效的一项公共卫生干预之一。
Chapter 6
Warfarin vs DOAC
Warfarin vs DOAC
Anticoagulant choice has gone through a paradigm shift in the past 15 years — most patients have moved from warfarin to DOACs (Direct Oral Anticoagulants).
Mechanism comparison:
Warfarin: inhibits VKORC1 → clotting factors II/VII/IX/X all inactivated (running through the K1 cycle); slow onset (3-5 days), slow offset (5-7 days)Dabigatran (Pradaxa): direct thrombin (IIa) inhibitor, doesn't touch KRivaroxaban (Xarelto) / apixaban (Eliquis) / edoxaban (Lixiana): direct factor Xa inhibitors, don't touch KDOAC shared features: onset 2-4 h, offset 1-2 days, no routine INR monitoring, dietary K doesn't affect drug action
Pivotal RCT — ARISTOTLE (Granger 2011, NEJM): 18,201 atrial fibrillation patients randomized to apixaban vs warfarin; apixaban reduced stroke / systemic embolism by 21%, major bleeding by 31%, all-cause mortality by 11%. RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and ENGAGE AF-TIMI 48 (edoxaban) gave directionally consistent results. So modern AF guidelines (AHA / ESC) list DOACs as first-line.
Scenarios where warfarin remains first choice (DOACs unsuitable or data insufficient):
Mechanical valves (RE-ALIGN negative — DOACs are contraindicated here)High-risk antiphospholipid syndrome (APS)Severe renal failure (eGFR < 15-30 — DOACs excluded or need dose adjustment)Pregnancy (warfarin is teratogenic but DOAC data are even thinner — LMWH is usually used)Cost: warfarin ¥30-80/month vs DOAC ¥500-2000/month
Warfarin + K1 dietary practical (if you're on warfarin): don't avoid all greens (that's the old wrong advice); eat about the same amount of greens daily (e.g., 1 cup cooked spinach/day) and let the physician dose warfarin against that baseline; suddenly eating 5 cups of spinach drops INR and raises clot risk; suddenly cutting greens raises INR and bleeding risk; the principle is 'stable + monitor + adjust dose', not 'avoid'. INR targets: AF / DVT / PE 2.0-3.0, mechanical valves 2.5-3.5. INR > 5 without bleeding: usually skip a dose and recheck; INR > 10 without bleeding: K1 2.5-5 mg PO; major bleeding: K1 10 mg IV + PCC + transfusion.
DOAC users have complete dietary freedom on K1 foods and K2 supplements — this is the real quality-of-life dividend of DOACs.
'Anticoagulant = warfarin' is a 30-year-old mental model. Most AF / DVT / PE patients today are recommended DOACs; warfarin remains the gold standard for mechanical valves, APS, and severe renal failure — so K1 knowledge still matters.
Mechanism comparison:
Warfarin: inhibits VKORC1 → clotting factors II/VII/IX/X all inactivated (running through the K1 cycle); slow onset (3-5 days), slow offset (5-7 days)Dabigatran (Pradaxa): direct thrombin (IIa) inhibitor, doesn't touch KRivaroxaban (Xarelto) / apixaban (Eliquis) / edoxaban (Lixiana): direct factor Xa inhibitors, don't touch KDOAC shared features: onset 2-4 h, offset 1-2 days, no routine INR monitoring, dietary K doesn't affect drug action
Pivotal RCT — ARISTOTLE (Granger 2011, NEJM): 18,201 atrial fibrillation patients randomized to apixaban vs warfarin; apixaban reduced stroke / systemic embolism by 21%, major bleeding by 31%, all-cause mortality by 11%. RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and ENGAGE AF-TIMI 48 (edoxaban) gave directionally consistent results. So modern AF guidelines (AHA / ESC) list DOACs as first-line.
Scenarios where warfarin remains first choice (DOACs unsuitable or data insufficient):
Mechanical valves (RE-ALIGN negative — DOACs are contraindicated here)High-risk antiphospholipid syndrome (APS)Severe renal failure (eGFR < 15-30 — DOACs excluded or need dose adjustment)Pregnancy (warfarin is teratogenic but DOAC data are even thinner — LMWH is usually used)Cost: warfarin ¥30-80/month vs DOAC ¥500-2000/month
Warfarin + K1 dietary practical (if you're on warfarin): don't avoid all greens (that's the old wrong advice); eat about the same amount of greens daily (e.g., 1 cup cooked spinach/day) and let the physician dose warfarin against that baseline; suddenly eating 5 cups of spinach drops INR and raises clot risk; suddenly cutting greens raises INR and bleeding risk; the principle is 'stable + monitor + adjust dose', not 'avoid'. INR targets: AF / DVT / PE 2.0-3.0, mechanical valves 2.5-3.5. INR > 5 without bleeding: usually skip a dose and recheck; INR > 10 without bleeding: K1 2.5-5 mg PO; major bleeding: K1 10 mg IV + PCC + transfusion.
DOAC users have complete dietary freedom on K1 foods and K2 supplements — this is the real quality-of-life dividend of DOACs.
'Anticoagulant = warfarin' is a 30-year-old mental model. Most AF / DVT / PE patients today are recommended DOACs; warfarin remains the gold standard for mechanical valves, APS, and severe renal failure — so K1 knowledge still matters.
Anticoagulant × vitamin K cheat sheet
You or a family member on anticoagulation? One table clarifies each anticoagulant's relationship to vitamin K:| Drug | Mechanism | Monitoring | K1 diet | K2 supplement |
|---|---|---|---|---|
| Warfarin | Blocks VKORC1 | INR every 1-4 weeks | Stable daily | Must ask MD |
| Dabigatran (Pradaxa) | Inhibits IIa | None routine | Free | Free |
| Apixaban (Eliquis) | Inhibits Xa | None routine | Free | Free |
| Rivaroxaban (Xarelto) | Inhibits Xa | None routine | Free | Free |
| Edoxaban (Lixiana) | Inhibits Xa | None routine | Free | Free |
| LMWH (Clexane) | Inhibits Xa / IIa | Anti-Xa (occasionally) | Free | Free |
| Aspirin | Inhibits platelets | None | Free | Free |
Common Q&A:
'I'm on aspirin, can I eat lots of spinach?' Yes — aspirin doesn't run through the K cycle.'I just started warfarin, do I have to give up greens?' No — eat about the same amount daily; tell your physician your normal greens portion and they dose against it.'I switched to apixaban; can I have the natto I avoided on warfarin?' Yes — DOACs don't care about K.'Elderly relative on warfarin, winter cuts vegetable intake, INR drifting up — what to do?' Real scenario; increase INR check frequency, may need a dose reduction.'Will K2 (MK-7) supplements antagonize warfarin?' Yes. K2 is also a KH₂ donor; any K form antagonizes warfarin — disclose to your physician before starting K2 and adjust dose accordingly.
Links to other Atlas stories:
vitamin-k2 L3 + L4 (osteocalcin + MGP)calcium + bone L3 (D / K2 / Ca triad)vitamin-d L3 (D-K-Ca synergy)cardiovascular / atherosclerosis L4 (vascular calcification)alcohol-metabolism / liver-disease (hepatic clotting factor synthesis)
One sentence: K1 is the clotting key in green leaves — food sources are abundant, and healthy people don't need a dedicated supplement; the practical question isn't 'enough or not', it's 'how to coordinate with medications'.
References · 6
- National Institutes of Health, Office of Dietary Supplements. (2021). Vitamin K — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/VitaminK-HealthProfessional
- Stafford, D. W. (2005). The vitamin K cycle. Journal of Thrombosis and Haemostasis, 3(8), 1873-1878. Reviews GGCX γ-carboxylation of factors II/VII/IX/X and VKORC1-mediated recycling of vitamin K epoxide — the molecular target of warfarin. 10.1111/j.1538-7836.2005.01419.x
- Shearer, M. J. (2009). Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Reviews, 23(2), 49-59. 10.1016/j.blre.2008.06.001
- American Academy of Pediatrics, Committee on Fetus and Newborn (Hand, I., Noble, L., & Abrams, S. A.). (2022). Vitamin K and the newborn infant. Pediatrics, 149(3), e2021056036. Recommends 0.5–1 mg IM phylloquinone within 6 h of birth to prevent VKDB. 10.1542/peds.2021-056036
- Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). New England Journal of Medicine, 365(11), 981-992. 10.1056/NEJMoa1107039
- Booth, S. L., Centurelli, M. A. (2004). Vitamin K: A practical guide to the dietary management of patients on warfarin. Nutrition Reviews, 62(3), 124-129. & supporting AHA 2003 statement on warfarin + dietary vitamin K consistency. 10.1111/j.1753-4887.2004.tb00033.x